MCID: MYC008
MIFTS: 59

Myocarditis

Categories: Cardiovascular diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Myocarditis

MalaCards integrated aliases for Myocarditis:

Name: Myocarditis 12 74 52 54 6 43 15 17 71
Myocardial Inflammation 12

Classifications:



External Ids:

Disease Ontology 12 DOID:820
ICD9CM 34 429.0
MeSH 43 D009205
NCIt 49 C34831
SNOMED-CT 67 50920009
ICD10 32 I41 I41.8 I51.4
UMLS 71 C0027059

Summaries for Myocarditis

NIH Rare Diseases : 52 Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus , Wegener's granulomatosis , giant cell arteritis and Takayasu's arteritis . Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.

MalaCards based summary : Myocarditis, also known as myocardial inflammation, is related to giant cell myocarditis and toxic myocarditis. An important gene associated with Myocarditis is CXADR (CXADR Ig-Like Cell Adhesion Molecule), and among its related pathways/superpathways are Viral myocarditis and Innate Immune System. The drugs Oseltamivir and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include heart, t cells and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An extrinsic cardiomyopathy that is characterized as an inflammation of the heart muscle.

Wikipedia : 74 Myocarditis, also known as inflammatory cardiomyopathy, is inflammation of the heart muscle. Symptoms... more...

Related Diseases for Myocarditis

Diseases in the Myocarditis family:

Acute Myocarditis Autoimmune Myocarditis
Infectious Myocarditis

Diseases related to Myocarditis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 904)
# Related Disease Score Top Affiliating Genes
1 giant cell myocarditis 35.1 MB HLA-B
2 toxic myocarditis 34.5 TNNI3 NPPB
3 acute myocarditis 34.4 TNNI3 NPPB IL6 CD86 CD40
4 drug reaction with eosinophilia and systemic symptoms 33.4 TNF HLA-B
5 chagas disease 33.0 TNF NPPB NOS2 IL6
6 cardiogenic shock 32.1 NPPB IL6
7 atrial standstill 1 31.8 TNNI3 NPPB MYH6 DSP DMD
8 dilated cardiomyopathy 31.7 TNNI3 TNF NPPB NOS2 MYH6 MB
9 congestive heart failure 31.6 TNNI3 TNF NPPB MYH6 IL6
10 lupus erythematosus 31.6 TNF HLA-DQB1 CD86 CD40LG CD40
11 exanthem 31.6 TNF IL6 CD40LG
12 myositis 31.6 TNF MB IL6 HLA-B DMD
13 sarcoidosis 1 31.6 TNF ICAM1 HLA-DQB1 CD86 CD40LG
14 endocarditis 31.6 TNNI3 TNF IL6
15 chickenpox 31.5 TNF IL6 CD40LG
16 pericarditis 31.5 TNNI3 TNF NPPB IL6 CD40LG
17 autoimmune disease 31.5 TNF IL6 HLA-DQB1 HLA-B CD86 CD55
18 mumps 31.5 TNF IL6 HLA-DQB1 CD40LG
19 pericardial effusion 31.4 TNNI3 NPPB IL6 CD40LG
20 cardiac arrest 31.4 NPPB MYH6 ICAM1 DSP
21 poliomyelitis 31.4 TNF ICAM1 CD40LG
22 myasthenia gravis 31.4 TNF HLA-DQB1 HLA-B CD86 CD55
23 typhoid fever 31.4 TNF IL6 HLA-DQB1 CD40LG
24 vasculitis 31.4 TNF ITGB2 IL6 ICAM1 HLA-B CD40LG
25 encephalitis 31.4 TNF NOS2 IL6 CD40LG
26 meningoencephalitis 31.4 TNF IL6 CD40LG
27 thyroiditis 31.3 TNF IL6 CD40
28 chlamydia 31.3 TNF NOS2 IL6 CD40LG
29 q fever 31.3 TNF IL6 CD40LG
30 pharyngitis 31.3 TNF IL6 CD40LG
31 dengue disease 31.2 TNF ICAM1 CD40LG
32 hypertrophic cardiomyopathy 31.2 TNNI3 MYH6 DSP DMD
33 leptospirosis 31.2 TNF IL6 CD40LG
34 chlamydia pneumonia 31.2 TNF IL6 CD40LG
35 guillain-barre syndrome 31.2 TNF HLA-DQB1 CD40LG
36 kawasaki disease 31.2 TNF NPPB IL6 CD40LG CD40
37 lyme disease 31.1 TNF IL6 HLA-DQB1 CD40LG
38 cytomegalovirus infection 31.1 TNF IL6 HLA-B
39 pneumonia 31.1 TNF MB IL6 ICAM1 CD40LG
40 mixed connective tissue disease 31.1 TNF IL6 CD40LG
41 toxoplasmosis 31.1 TNF NOS2 IL6 HLA-DQB1 CD40LG CD40
42 proteasome-associated autoinflammatory syndrome 1 31.1 TNF NOS2 IL6 ICAM1
43 bronchopneumonia 31.1 TNF IL6 CD40LG
44 toxic shock syndrome 31.1 TNF NOS2 IL6 CD86 CD40LG CD40
45 dengue hemorrhagic fever 31.1 TNF IL6 HLA-B CD40LG
46 brucellosis 31.1 TNF IL6 CD86 CD40LG
47 rheumatic heart disease 31.1 TNF NPPB IL6
48 immune deficiency disease 31.1 TNF ITGB2 IL6 HLA-B CD40LG CD40
49 glomerulonephritis 31.0 NOS2 ICAM1 CD55 CD40LG
50 left bundle branch hemiblock 31.0 TNNI3 NPPB DSP

Comorbidity relations with Myocarditis via Phenotypic Disease Network (PDN):


Acute Cystitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Mitral Valve Disease

Graphical network of the top 20 diseases related to Myocarditis:



Diseases related to Myocarditis

Symptoms & Phenotypes for Myocarditis

GenomeRNAi Phenotypes related to Myocarditis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CD40LG DAG1 HLA-DQB1 ICAM1 NOS2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CD40 CD40LG DAG1 HLA-DQB1 ICAM1 NOS2

MGI Mouse Phenotypes related to Myocarditis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 CD40LG CXADR DAG1 DMD DSP HLA-DQB1
2 cellular MP:0005384 10.32 CD40LG CD86 CXADR DAG1 DMD DSP
3 hematopoietic system MP:0005397 10.22 CD40 CD40LG CD55 CD86 CXADR DMD
4 homeostasis/metabolism MP:0005376 10.21 CD40 CD40LG CD86 CXADR DAG1 DMD
5 endocrine/exocrine gland MP:0005379 10.13 CD40 CD40LG CD86 CXADR DMD HLA-DQB1
6 immune system MP:0005387 10.1 CD40 CD40LG CD86 CXADR DMD HLA-DQB1
7 mortality/aging MP:0010768 10.1 CD40LG CXADR DAG1 DMD DSP HLA-DQB1
8 digestive/alimentary MP:0005381 10.06 CXADR DMD DSP HLA-DQB1 ICAM1 IL6
9 muscle MP:0005369 9.97 CD86 CXADR DAG1 DMD DSP HLA-DQB1
10 nervous system MP:0003631 9.7 CD40 CD40LG CD86 DAG1 DMD DSP
11 respiratory system MP:0005388 9.28 CXADR DMD HLA-DQB1 IL6 MB MYH6

Drugs & Therapeutics for Myocarditis

Drugs for Myocarditis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
2
Abatacept Approved Phase 4 332348-12-6 10237
3
Adalimumab Approved Phase 4 331731-18-1 16219006
4 Anti-Inflammatory Agents Phase 4
5 Immunosuppressive Agents Phase 4
6 Immunologic Factors Phase 4
7 Rho(D) Immune Globulin Phase 4
8 Immunoglobulins Phase 4
9 Immunoglobulins, Intravenous Phase 4
10 gamma-Globulins Phase 4
11 Antibodies Phase 4
12 Vaccines Phase 4
13 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
14 Hypoglycemic Agents Phase 4
15 Sodium-Glucose Transporter 2 Inhibitors Phase 4
16
Bisoprolol Approved Phase 3 66722-44-9 2405
17
Ramipril Approved Phase 3 87333-19-5 5362129
18
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
19
Captopril Approved Phase 3 62571-86-2 44093
20
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
21
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198
22 Neurotransmitter Agents Phase 3
23 Hematinics Phase 2, Phase 3
24 Ferrosoferric Oxide Phase 2, Phase 3
25 Parenteral Nutrition Solutions Phase 2, Phase 3
26 Protective Agents Phase 3
27 Autonomic Agents Phase 3
28 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
29 Adrenergic Antagonists Phase 2, Phase 3
30 Adrenergic beta-Antagonists Phase 2, Phase 3
31 Adrenergic Agents Phase 2, Phase 3
32
protease inhibitors Phase 3
33 HIV Protease Inhibitors Phase 3
34 Adrenergic beta-1 Receptor Antagonists Phase 3
35 Angiotensin-Converting Enzyme Inhibitors Phase 3
36 Sympatholytics Phase 3
37 Antioxidants Phase 3
38 Trace Elements Phase 3
39 Micronutrients Phase 3
40 Nutrients Phase 3
41 Sodium Selenite Phase 3
42 Antihypertensive Agents Phase 3
43 Angiotensin Receptor Antagonists Phase 3
44 Angiotensin II Type 1 Receptor Blockers Phase 3
45 Giapreza Phase 3
46 LCZ 696 Phase 3
47 Angiotensinogen Phase 3
48
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
49
Lenograstim Approved, Investigational Phase 2 135968-09-1
50
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
2 Effects of Abatacept on Myocarditis in Rheumatoid Arthritis Recruiting NCT03619876 Phase 4 Abatacept;Adalimumab
3 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
4 Effects of SGLT-2 Inhibition With Dapagliflozin on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI With T1- and T2-mapping in Patients With Type-2 Diabetes Recruiting NCT03782259 Phase 4 dapagliflozin
5 RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESSIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATHY IMMUNOSUPPRESSION TRIAL) Unknown status NCT01877746 Phase 3 Combination of prednisone and azathioprine;Combination of prednisone and azathioprine
6 Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection Unknown status NCT02787382 Phase 3
7 DEtection of Cellular Inflammation With FERumoxytol in the HEART Completed NCT02319278 Phase 2, Phase 3 Ferumoxytol
8 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
9 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
10 Anakinra Versus Placebo Double Blind Randomized Controlled Trial for the Treatment of Acute MyocarditIS Recruiting NCT03018834 Phase 2, Phase 3 ANAKINRA 100 mg/daily subcutaneously;Placebo
11 Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo)Adjuvant Anthracyclines and/or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial Recruiting NCT02236806 Phase 3 Bisoprolol;Ramipril;Placebo
12 Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
13 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Recruiting NCT03389724 Phase 3 Capoten®
14 PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction Not yet recruiting NCT04128891 Phase 3 Sacubitril-Valsartan
15 Application of Sildenafil in Patients With Documented Coronary Vasospasm to Explore the Pathophysiology of Coronary Vasospasm and the Therapeutic Effect of Sildenafil in Patients Suffering From Coronary Vasospasm Withdrawn NCT00454714 Phase 3 single dose Sildenafil;Single dose placebo
16 Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation. Withdrawn NCT02582190 Phase 3 Colchicine group
17 Prospective, Double-blind, Randomized, Placebo-controlled Phase II Clinical Trial for Evaluation of G-CSF in Patients With Chronic Chagas Cardiomyopathy Unknown status NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
18 ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION Application Of Ultrasmall Superparamagnetic Particles Of Iron Oxide Unknown status NCT01995799 Phase 2
19 Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis Completed NCT00004482 Phase 2 Cyclosporine;methylprednisolone;Muromonab-CD3;prednisone
20 Myocarditis Treatment Trial Completed NCT00000524 Phase 2 cyclosporine;prednisone
21 Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years) Completed NCT01554943 Phase 2
22 Double Blinded Placebo Controlled Study to Assess Clinical and Antiviral Activity of Valganciclovir (VAL) in Solid Organ Transplant Donors to Reduce Viral Transmission From Donor to Recipient Completed NCT01329185 Phase 2 Valganciclovir;Placebo
23 A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates With Enteroviral Sepsis Syndrome Completed NCT00031512 Phase 2 Placebo;Pleconaril (VP63843)
24 Safety and Tolerability of Sodium Thiosulfate in Patients Presenting With an Acute Coronary Syndrome Undergoing Coronary Angiography Via Trans-radial Approach: a Dose-escalation Study. Completed NCT03017963 Phase 1, Phase 2 Sodium Thiosulfate Pentahydrate
25 Outcome of Myocardial Inflammation After Steroid Therapy in Thai Systemic Sclerosis Patients: an Open Label Study Recruiting NCT03607071 Phase 2 Prednisolone and taper
26 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation Recruiting NCT03103490 Phase 2 18F-FSPG
27 Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease Recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
28 Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study Recruiting NCT03515304 Phase 2 Evolocumab;Placebo
29 Evolocumab in Patients With ST Elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study Recruiting NCT04082442 Phase 2 Evolocumab;Placebos
30 Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2: Evaluation of Biomarkers of Immunologic and Therapeutic Response Recruiting NCT01884961 Phase 2
31 ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial Recruiting NCT03004703 Phase 2 Tocilizumab;Sodium chloride 0.9%
32 Groningen Intervention Study for the Preservation of Cardiac Function With Sodium Thiosulfate After ST-segment Elevation Myocardial Infarction Recruiting NCT02899364 Phase 2 Sodium thiosulfate;Sodium chloride 0.9%
33 Rapid Recovery of Left Ventricular Function in Patients With Takotsubo Syndrome Undergoing Systemic Infusion of Adenosine: a Randomized Controlled Trial (TITAN Study) Terminated NCT02867878 Phase 2 Adenosine;Saline solution
34 A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients Terminated NCT00311987 Phase 1, Phase 2 3,5-Diiodothyropropionic acid (DITPA) therapy
35 The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity Completed NCT00530101 Phase 1 Doxorubicin
36 Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers Completed NCT01433835 Phase 1 MBX-400
37 Prospective Assessment of the Clinical Utility of Cardiovascular Magnetic Resonance in Patients With Suspected Acute Myocarditis - A Pilot Study for Establishing an International Registry Unknown status NCT01307735
38 Myocardial Inflammation in Systemic Lupus Erythematosus Unknown status NCT01761422
39 2D and Tissue Doppler Imaging Echocardiography Analysis of Left Ventricular Regional Wall Motion and Prognosis Unknown status NCT01092429
40 DZHK TranslatiOnal Registry for CardiomyopatHies Deutsches Zentrum für Herz- Und Kreislauf-Forschung (DZHK) Unknown status NCT02187263
41 Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases- A New Method to Improve Patient Care Unknown status NCT03199001
42 Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications Unknown status NCT02062008
43 Transient ECG Changes in Patients With Acute Biliary Disease Unknown status NCT01706068
44 Genetics of Innate Immune Response After Burn Trauma Unknown status NCT00294697
45 Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in ECMO Patients Unknown status NCT01089036
46 Effect of Intermittent Normoxic Cardiopulmonary Bypass on Myocardial Reperfusion Injury in Adult Valve Replacement Unknown status NCT01348906
47 The Role of Functional Active Anti-Angiotensin-Receptor 1 (ATR1)- and Anti-Endothelin-Receptor A (ETRA)-Antibodies and Autoreactive T Cells in Cardiomyopathy Unknown status NCT02319590
48 The Use of Cardiovascular Biomarkers in Abdominal Aortic Surgery: Possibility of Risk Assessment and Stratification Unknown status NCT02122497
49 Consolidating Tools for Outcomes in Resuscitation (CONTOUR) Unknown status NCT02676024
50 Myocarditis and the Role of Advanced Magnetic Resonance Imaging Completed NCT02177630

Search NIH Clinical Center for Myocarditis

Cochrane evidence based reviews: myocarditis

Genetic Tests for Myocarditis

Anatomical Context for Myocarditis

MalaCards organs/tissues related to Myocarditis:

40
Heart, T Cells, Liver, Endothelial, Lung, Monocytes, Brain

Publications for Myocarditis

Articles related to Myocarditis:

(show top 50) (show all 15104)
# Title Authors PMID Year
1
Cardiac involvement in a female carrier of Duchenne muscular dystrophy. 54 61
18706718 2010
2
IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection. 54 61
19896686 2010
3
Remodeling of dystrophin and sarcomeric Z-band occurs in pediatric cardiomyopathies: a unifying mechanism for force transmission defect. 54 61
19194174 2009
4
Cardiac natriuretic peptides gene expression and secretion in inflammation. 54 61
19158604 2009
5
Activation of STAT1 transcription factor precedes up-regulation of coxsackievirus-adenovirus receptor during viral myocarditis. 54 61
18329552 2008
6
[The expression of coxsackie B virus adenovirus receptor (CAR) in viral myocarditis and dilated cardiomyopathy patients]. 54 61
17896511 2007
7
From oxygen sensing to heart failure: role of thioredoxin. 54 61
17511584 2007
8
Determinants of brain natriuretic peptide gene expression and secretion in acute cardiac allograft rejection. 54 61
17284995 2007
9
[Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice]. 54 61
17254452 2006
10
Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rbeta1 signaling and IFN-gamma increase inflammation in males independent from STAT4. 54 61
16949558 2006
11
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. 54 61
17039570 2006
12
Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. 54 61
16806133 2006
13
TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis. 54 61
16631119 2006
14
[The expression of dystrophin in human viral myocarditis and dilated cardiomyopathy]. 54 61
16524176 2006
15
The osteopontin - CD44 pathway is superfluous for the development of autoimmune myocarditis. 54 61
16402410 2006
16
Is diagnostic myocardial biopsy useful in the XXI century? 54 61
15928740 2005
17
Successful treatment of experimental autoimmune myocarditis by adenovirus-mediated gene transfer of antisense CIITA. 54 61
15808836 2005
18
Exogenous thioredoxin reduces inflammation in autoimmune myocarditis. 54 61
15353510 2004
19
Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. 54 61
15218506 2004
20
Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. 54 61
12920582 2004
21
Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat. 54 61
14624362 2004
22
Animal models for autoimmune myocarditis and autoimmune thyroiditis. 54 61
15286386 2004
23
Upregulation of redox-regulating protein, thioredoxin, in endomyocardial biopsy samples of patients with myocarditis and cardiomyopathies. 54 61
12870673 2003
24
Viral causes of cardiac inflammation. 54 61
12826818 2003
25
Analysis of the coxsackievirus B-adenovirus receptor gene in patients with myocarditis or dilated cardiomyopathy. 54 61
12409275 2002
26
Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. 54 61
12018720 2002
27
Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. 54 61
11901182 2002
28
The role of interferon regulatory factors in the cardiac response to viral infection. 54 61
11952139 2002
29
Molecular genetics of left ventricular dysfunction. 54 61
11899244 2001
30
Arrhythmogenic inherited heart muscle diseases in children. 54 61
11781950 2001
31
Interferon regulatory factor 3 is required for viral induction of beta interferon in primary cardiac myocyte cultures. 54 61
10559337 1999
32
Anti-mitochondrial antibodies in patients with dilated cardiomyopathy (anti-M7) are directed against flavoenzymes with covalently bound FAD. 54 61
9528896 1998
33
Cardiac troponin T in patients with clinically suspected myocarditis. 54 61
9350939 1997
34
iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. 54 61
9244230 1997
35
Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. 54 61
8978317 1997
36
Venticular expression of atrial and brain natriuretic peptides in patients with myocarditis. 54 61
8789180 1995
37
Role of nitric oxide in the regulation of myocardial function. 54 61
7568904 1995
38
A case of creatine kinase isomer anomaly in relation to the diagnosis of acute myocardial infarction. 54 61
8051787 1994
39
[Autoantibodies against the beta 1-adrenergic receptor in myocarditis and dilated cardiomyopathy: localization of two epitopes]. 54 61
1283934 1992
40
[The significance of myoglobin determination in the differential diagnosis of chest pain syndrome]. 54 61
2053302 1991
41
Relation between myoglobin and cardiac dysfunction in myocarditis--immunohistochemical study of endomyocardial biopsy specimens. 54 61
2010944 1991
42
Clinicopathological manifestations of myocarditis in a heart failure population. 61
31896440 2020
43
IL-1-dependent electrophysiological changes and cardiac neural remodeling in a mouse model of Kawasaki disease vasculitis. 61
31758701 2020
44
Viral Myocarditis. 61
32000238 2020
45
Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. 61
31838162 2020
46
Ocular myasthenia gravis: updates on an elusive target. 61
31789705 2020
47
A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis. 61
32020498 2020
48
Acute myocardial infarction in a young woman: Unexpected findings of a coronary occlusion. 61
31896072 2020
49
Microvascular spasm in non-ST-segment elevation myocardial infarction without culprit lesion (MINOCA). 61
31236694 2020
50
Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. 61
31561995 2020

Variations for Myocarditis

ClinVar genetic disease variations for Myocarditis:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABCD1 NM_000033.4(ABCD1):c.1866-1G>CSNV Likely pathogenic 523312 rs1557055311 X:153008674-153008674 X:153743220-153743220
2 AMER1 NM_152424.4(AMER1):c.1907_1908GA[2] (p.Glu637fs)short repeat Uncertain significance 523561 rs1555933313 X:63411255-63411256 X:64191375-64191376

Expression for Myocarditis

Search GEO for disease gene expression data for Myocarditis.

Pathways for Myocarditis

Pathways related to Myocarditis according to KEGG:

36
# Name Kegg Source Accession
1 Viral myocarditis hsa05416

Pathways related to Myocarditis according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 TNF NOS2 ITGB2 IL6 ICAM1 HLA-DQB1
2
Show member pathways
13.42 ITGB2 ICAM1 HLA-DQB1 HLA-B CXADR CD86
3
Show member pathways
13.3 TNF NOS2 ITGB2 IL6 ICAM1 HLA-DQB1
4
Show member pathways
12.78 TNF IL6 ICAM1 HLA-DQB1 HLA-B CD40
5
Show member pathways
12.61 TNF HLA-DQB1 CD86 CD40LG CD40
6
Show member pathways
12.36 HLA-DQB1 CD86 CD40LG CD40
7
Show member pathways
12.31 NOS2 MYH6 ITGB2 ICAM1
8
Show member pathways
12.23 TNF NOS2 ITGB2 HLA-DQB1 CD40LG CD40
9 12.21 TNF ITGB2 IL6 ICAM1 HLA-DQB1 HLA-B
10
Show member pathways
12.21 TNF MYH6 ITGB2 IL6 ICAM1 HLA-DQB1
11 12.2 TNF NOS2 ITGB2 IL6 HLA-DQB1
12
Show member pathways
12.2 TNNI3 TNF MYH6 IL6 DMD DAG1
13
Show member pathways
12.02 TNF ITGB2 IL6 CD40
14 12.01 ITGB2 ICAM1 DSP CXADR
15 11.99 TNF NOS2 IL6 ICAM1
16 11.98 ITGB2 ICAM1 HLA-B CXADR CD40LG CD40
17 11.97 TNF NOS2 ITGB2 IL6 ICAM1
18 11.9 TNF ICAM1 CD40LG CD40
19 11.89 TNF NOS2 ITGB2 IL6
20 11.87 TNF IL6 HLA-DQB1 CD55
21 11.87 ITGB2 ICAM1 HLA-DQB1 HLA-B CD86 CD40LG
22 11.74 TNF NOS2 ITGB2 IL6
23
Show member pathways
11.72 TNF CD40LG CD40
24 11.71 TNNI3 MYH6 DMD
25 11.7 TNF ITGB2 IL6 ICAM1 HLA-DQB1 CD86
26 11.68 TNF NOS2 IL6 CD86 CD40
27 11.64 TNF IL6 DSP
28 11.6 CD86 CD40LG CD40
29
Show member pathways
11.6 TNF NOS2 IL6 ICAM1 CD40LG
30 11.59 TNF ITGB2 IL6
31 11.55 CD86 CD40LG CD40
32 11.53 TNF IL6 ICAM1 CD86
33 11.51 TNF ITGB2 IL6 ICAM1
34 11.49 TNF NOS2 ITGB2
35 11.38 NOS2 ICAM1 HLA-B
36 11.37 TNF IL6 ICAM1
37 11.31 CD86 CD40LG CD40
38 11.13 TNF ITGB2 IL6 ICAM1 CD40LG CD40
39 10.57 NOS2 MB

GO Terms for Myocarditis

Cellular components related to Myocarditis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.17 TNF NOS2 ITGB2 ICAM1 HLA-DQB1 HLA-B
2 extracellular exosome GO:0070062 10.09 MB ITGB2 ICAM1 HLA-B DSP DAG1
3 cell GO:0005623 9.86 TNNI3 NOS2 IL6 ICAM1 DMD DAG1
4 cell surface GO:0009986 9.81 TNF ITGB2 ICAM1 HLA-B DMD CD86
5 filopodium GO:0030175 9.63 DMD DAG1 CXADR
6 ficolin-1-rich granule membrane GO:0101003 9.58 ITGB2 DSP CD55
7 myofibril GO:0030016 9.54 TNNI3 MYH6 DMD
8 membrane raft GO:0045121 9.5 TNF ITGB2 ICAM1 DMD DAG1 CXADR
9 external side of plasma membrane GO:0009897 9.23 TNF ITGB2 ICAM1 HLA-B DAG1 CD86

Biological processes related to Myocarditis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.96 TNF ITGB2 IL6 CD40LG CD40
2 immune response GO:0006955 9.95 TNF IL6 HLA-DQB1 HLA-B CD86 CD40LG
3 extracellular matrix organization GO:0030198 9.91 TNF ITGB2 ICAM1 DAG1
4 viral process GO:0016032 9.91 ICAM1 HLA-B DAG1 CXADR CD86 CD55
5 leukocyte migration GO:0050900 9.88 TNF ITGB2 ICAM1 CXADR
6 cytokine-mediated signaling pathway GO:0019221 9.85 TNF NOS2 ITGB2 IL6 ICAM1 CD86
7 regulation of immune response GO:0050776 9.8 ITGB2 ICAM1 HLA-B CXADR CD40LG CD40
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNF IL6 CD40
9 interferon-gamma-mediated signaling pathway GO:0060333 9.77 ICAM1 HLA-DQB1 HLA-B
10 positive regulation of T cell proliferation GO:0042102 9.74 IL6 CD86 CD40LG
11 cardiac muscle contraction GO:0060048 9.71 TNNI3 MYH6 DMD
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 TNF ITGB2 ICAM1
13 muscle filament sliding GO:0030049 9.67 TNNI3 MYH6 DMD
14 leukocyte cell-cell adhesion GO:0007159 9.63 ITGB2 ICAM1 CD40LG
15 positive regulation of neuroinflammatory response GO:0150078 9.62 TNF IL6
16 cardiac muscle fiber development GO:0048739 9.62 MYH6 CXADR
17 response to denervation involved in regulation of muscle adaptation GO:0014894 9.61 DMD DAG1
18 negative regulation of lipid storage GO:0010888 9.58 TNF IL6
19 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.58 TNF ITGB2 ICAM1
20 CD40 signaling pathway GO:0023035 9.55 CD40LG CD40
21 viral entry into host cell GO:0046718 9.55 ICAM1 DAG1 CXADR CD86 CD55
22 cellular extravasation GO:0045123 9.51 TNF ITGB2
23 regulation of immunoglobulin secretion GO:0051023 9.43 TNF CD40LG CD40
24 cellular response to lipopolysaccharide GO:0071222 9.43 TNF NOS2 IL6 ICAM1 CD86 CD40
25 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.1 TNF ITGB2 IL6 ICAM1 CD40LG CD40

Molecular functions related to Myocarditis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TNNI3 TNF NPPB NOS2 MYH6 ITGB2
2 signaling receptor activity GO:0038023 9.67 ITGB2 ICAM1 CD86 CD40
3 cell adhesion molecule binding GO:0050839 9.43 ITGB2 DSP CXADR
4 vinculin binding GO:0017166 9.4 DMD DAG1
5 integrin binding GO:0005178 9.35 ITGB2 ICAM1 DMD CXADR CD40LG
6 dystroglycan binding GO:0002162 9.32 DMD DAG1
7 virus receptor activity GO:0001618 9.02 ICAM1 DAG1 CXADR CD86 CD55

Sources for Myocarditis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....